Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 3, 2008

Proteomika Licenses Auguron Technology to Advance Diagnostic Development in Autoimmune Diseases

  • Proteomika inked an option agreement for exclusive access to Auguron’s nucleic acid programmable protein array (NAPPA) technology in two autoimmune disease areas.

    The pact allows Proteomika to manufacture and use NAPPA technology for internal purposes as well as a service to partners. At any time during the agreement, Proteomika may exercise an option to negotiate an exclusive license to use NAPPA for IBD and lupus biomarker discovery.

    NAPPA technology enables the generation of fresh, functional proteins on high-density microchips from surface printed DNA. It was developed at the Harvard Institute of Proteomics (HIP) and is covered by several issued and pending patents licensed exclusively to Auguron Biosciences.

    Auguron was formed in early 2007 to commercialize developments at HIP. “This is the first disease-specific commercial venture for NAPPA and this option sets the stage for Proteomika to fully exploit the power of the platform in two very important disease areas,” says Jim Richey, co-founder and chief executive of Auguron.

    Proteomika is a subsidiary of Progenika Biopharma, which has developed and clinically validated LIPOchip®, a microarray for the diagnosis of familial hypercholesterolemia, PHARMAchip®, a drug metabolism genotyping microarray, and BLOODchip®, a blood group genotyping microarray. A series of new diagnostic microarrays are under development or in late-stage clinical validation, including products targeting fibromyalgia, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, osteoarthritis and osteoporosis.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »